We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Phasebio Pharmaceutical Inc (PHAS) USD0.001

Sell:$0.79 Buy:$0.84 Change: $0.0051 (0.64%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $0.0051 (0.64%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $0.0051 (0.64%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of therapies for cardiopulmonary diseases. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The Company conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.

Contact details

1 Great Valley Pkwy Ste 30
United States
+1 (610) 9816500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$39.03 million
Shares in issue:
48.69 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Clay Thorp
    Independent Chairman of the Board, Co-Founder
  • Jonathan Mow
    Chief Executive Officer, Director
  • John Sharp
    Chief Financial Officer
  • Kristophe Hanson
    Senior Vice President, General Counsel, Company Secretary
  • Glen Burkhardt
    Senior Vice President of Human Resources
  • Susan Arnold
    Senior Vice President - Technical Operations
  • Jonathan Birchall
    Chief Commercial Officer
  • John Lee
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.